Antibodies binding to citrullinated telopeptides of type I and type II collagens and to mutated citrullinated vimentin synergistically predict the development of seropositive rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 71, Issue 10, 2012, Pages 1666-1670

  Koivula, Marja Kaisa ^a,b   Heliövaara, Markku ^c   Rissanen, Harri ^c   Palosuo, Timo ^c   Knekt, Paul ^c   Immonen, Heikki ^a   Risteli, Juha ^a  

^a UNIVERSITY OF OULU   (Finland)

^b KAINUU CENTRAL HOSPITAL   (Finland)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE ANTIBODY; CARBOXY TERMINAL TYPE 2 COLLAGEN TELOPEPTIDE ANTIBODY; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; MUTATED CITRULLINATED VIMENTIN ANTIBODY; PEPTIDE ANTIBODY; RHEUMATOID FACTOR; UNCLASSIFIED DRUG;

ADULT; ANTIBODY BLOOD LEVEL; ANTIGEN BINDING; ARTICLE; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; ETHNIC GROUP; FEMALE; FINNISH; HUMAN; IMMUNOPATHOGENESIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; AUTOANTIGENS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CITRULLINE; COLLAGEN TYPE I; COLLAGEN TYPE II; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MUTATION; VIMENTIN;

EID: 84866131882     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2011-200848     Document Type: Article

References (31)

1. Koivula MK, Aman S, Karjalainen A, et al. Are there autoantibodies reacting against citrullinated peptides derived from type I and type II collagens in patients with rheumatoid arthritis? Ann Rheum Dis 2005;64:1443-50. (Pubitemid 41623855)
2. Koivula MK, Ramberg J, Aman S, et al. Sensitive immunoassays for the autoantibodies reacting against citrullinated carboxy-terminal telopeptides of type I and type II collagens in patients with rheumatoid arthritis. Clin Chem Lab Med 2005;43:1400-5. (Pubitemid 41752572)
3. Koivula MK, Heliövaara M, Ramberg J, et al. Autoantibodies binding to citrullinated telopeptide of type II collagen and to cyclic citrullinated peptides predict synergistically the development of seropositive rheumatoid arthritis. Ann Rheum Dis 2007;66:1450-5.
4. Rantapää-Dahlqvist S. What happens before the onset of rheumatoid arthritis? Curr Opin Rheumatol 2009;21:272-8.
5. Aho K, Palosuo T, Raunio V, et al. When does rheumatoid disease start? Arthritis Rheum 1985;28:485-9. (Pubitemid 15109897)
6. Aho K, Palosuo T, Heliövaara M, et al. Antifilaggrin antibodies within 'normal' range predict rheumatoid arthritis in a linear fashion. J Rheumatol 2000;27:2743-6.
7. Kurki P, Aho K, Palosuo T, et al. Immunopathology of rheumatoid arthritis. Antikeratin antibodies precede the clinical disease. Arthritis Rheum 1992;35:914-17.
8. Rantapää-Dahlqvist S, de Jong BA, Berglin E, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003;48:2741-9.
9. Pruijn GJ, Wiik A, van Venrooij WJ. The use of citrullinated peptides and proteins for the diagnosis of rheumatoid arthritis. Arthritis Res Ther 2010;12:203.
10. Nishimura K, Sugiyama D, Kogata Y, et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 2007;146:797-808. (Pubitemid 351650500)
11. Van de Stadt LA, de Koning MH, van de Stadt RJ, et al. Development of the anti-citrullinated protein antibody repertoire prior to the onset of rheumatoid arthritis. Arthritis Rheum 2011;63:3226-33.
12. van der Woude D, Rantapää-Dahlqvist S, Ioan-Facsinay A, et al. Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis. Ann Rheum Dis 2010;69:1554-61.
13. Nijenhuis S, Zendman AJ, Vossenaar ER, et al. Autoantibodies to citrullinated proteins in rheumatoid arthritis: clinical performance and biochemical aspects of an RA-specific marker. Clin Chim Acta 2004;350:17-34. (Pubitemid 39458243)
14. Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010;69:1580-8.
15. Van Steendam K, Tilleman K, Deforce D. The relevance of citrullinated vimentin in the production of antibodies against citrullinated proteins and the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford) 2011;50:830-7.
16. Bang H, Egerer K, Gauliard A, et al. Mutation and citrullination modifi es vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum 2007;56:2503-11. (Pubitemid 47237269)
17. Poulsom H, Charles PJ. Antibodies to citrullinated vimentin are a specific and sensitive marker for the diagnosis of rheumatoid arthritis. Clin Rev Allergy Immunol 2008;34:4-10.
18. Soós L, Szekanecz Z, Szabó Z, et al. Clinical evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis. J Rheumatol 2007;34:1658-63.
19. Ursum J, Nielen MM, van Schaardenburg D, et al. Antibodies to mutated citrullinated vimentin and disease activity score in early arthritis: a cohort study. Arthritis Res Ther 2008;10:R12.
20. Wagner E, Skoumal M, Bayer PM, et al. Antibody against mutated citrullinated vimentin: a new sensitive marker in the diagnosis of rheumatoid arthritis. Rheumatol Int 2009;29:1315-21.
21. Luime JJ, Colin EM, Hazes JM, et al. Does anti-mutated citrullinated vimentin have additional value as a serological marker in the diagnostic and prognostic investigation of patients with rheumatoid arthritis? A systematic review. Ann Rheum Dis 2010;69:337-44.
22. Koivula MK, Aman S, Alasaarela E, et al. Inhibitory characteristics of citrullinated telopeptides of type I and II collagens for autoantibody binding in patients with rheumatoid arthritis. Rheumatology (Oxford) 2006;45:1364-9. (Pubitemid 44605470)
23. Heliövaara M, Aho K, Aromaa A, et al. Smoking and risk of rheumatoid arthritis. J Rheumatol 1993;20:1830-5.
24. Hakala M, Pöllänen R, Nieminen P. The ARA 1987 revised criteria select patients with clinical rheumatoid arthritis from a population based cohort of subjects with chronic rheumatic diseases registered for drug reimbursement. J Rheumatol 1993;20:1674-8. (Pubitemid 24017568)
25. Kaipiainen-Seppänen O, Aho K, Isomäki H, et al. Shift in the incidence of rheumatoid arthritis toward elderly patients in Finland during 1975-1990. Clin Exp Rheumatol 1996;14:537-42.
26. Knekt P, Aromaa A, Maatela J, et al. Serum vitamin E and risk of cancer among Finnish men during a 10-year follow-up. Am J Epidemiol 1988;127:28-41. (Pubitemid 18034363)
27. Breslow NE, Day NE. Statistical methods in cancer research: Volume I. The analysis of case-control studies. IARC Sci Publ 1980;32:5-338.
28. Aho K, Heliövaara M. Risk factors for rheumatoid arthritis. Ann Med 2004;36:242-51. (Pubitemid 38796483)
29. Wegner N, Wait R, Sroka A, et al. Peptidylarginine deiminase from Porphyromonas gingivalis citrullinates human fibrinogen and α-enolase: implications for autoimmunity in rheumatoid arthritis. Arthritis Rheum 2010;62:2662-72.
30. Wang Z, Nicholls SJ, Rodriguez ER, et al. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med 2007;13:1176-84. (Pubitemid 47530630)
31. Turunen S, Koivula MK, Risteli L, et al. Anticitrulline antibodies can be caused by homocitrulline-containing proteins in rabbits. Arthritis Rheum 2010;62:3345-52.